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1. GENERAL INTRODUCTION: 
 
1.1 The Acute Coronary Syndrome (ACS)  
Cardiovascular disease, one of the leading causes of death in the 
western society, is also becoming a major health challenge in developing countries such 
as India, Brazil and China (1). Implementation of a western lifestyle including cigarette 
smoking, physical inactivity and a diet rich in carbohydrates and unsaturated fats has 
resulted in increasing obesity, associated diabetes and early manifestation of 
atherosclerosis, all leading to a growing rate of cardiovascular disease in developing 
countries (1-4). Likewise, Argentina is facing a similar challenge with respect to pre-stage 
cardiovascular disease, with a growing prevalence of diabetes (10%), hypertension (36%) 
and smoking habits (28%). A similar prevalence is found in the province of Salta (5).  
Chest pain is the main symptom of both chronic and acute coronary 
heart disease (CHD). However, chest pain is also the main symptom of other thoraco-
pulmonary conditions, and to distinguish ACS patients among a population admitted with 
chest pain represents a diagnostic challenge.  
The classification of patients with ACS is based on the 
electrocardiogram (ECG).  As such, two categories of patients may be encountered: 1. 
patients with typical acute chest pain (>20 min) and persistent ST-segment elevation, 
termed ST-elevation ACS (STE-ACS) or ST-segment elevation myocardial infarction 
(STEMI), and 2. patients with acute chest pain but without persistent ST-segment 
elevation (NSTE-ACS). Based on the measurement of troponins, these patients are further 
classified into non-ST elevation MI (NSTEMI) or unstable angina pectoris (UAP) (6). In 
the present setting we have added troponin T (TnT) in the diagnosis of ACS. 
Atherosclerotic plaque rupture or erosion, with differing degrees of 
superimposed thrombosis and distal embolization, results in myocardial underperfusion, 
and represents the main pathophysiological mechanism of ACS (7).  
Risk assessment in ACS should include several prognostic indicators 
of future ischemic events. In the present study we have focused on various biomarkers 
known to be associated with CHD, such as TnT, B-type natriuretic peptide (BNP), and 
high sensitivity C-reactive protein (hsCRP). In addition to these we have evaluated the 
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prognostic significance of vitamin D and omega-3 index [the sum of eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA)]. 
Risk assessment in a general setting constitutes several clinical 
parameters, including gender, age, smoking, hypertension, index diagnosis, diabetes 
mellitus (DM), congestive heart failure (CHF)(8), history of previous CHD and 
medication. These need to be corrected for when evaluating the prognostic utility of the 
individual biomarker. Women are also different from men with respect to risk assessment, 
and this has been focused on in a socioeconomic setting.  
 
1.2 Population 
1.2.1 City Characteristics 
The studied population is from the city of Salta, the capital of the 
Province of Salta in Northern Argentina. The city of Salta is located in the Lerma Valley, 
1152 meters (3780 feet) above sea level, at the foothills of the Andes mountains. The 
metropolitan area has a population of 619,000 inhabitants, which makes it the second 
most populated city in the northwestern part of the country. The province of Salta has 
1,210,000 inhabitants (9). The climate in Salta is highland subtropical [according to the 
Köppen-Geiger climate classification (10)], and the city is located at 24 degrees latitude 
south of the Equator.  
Based on its inland location and its livestock economy and traditions, 
beef, and not fish, forms the main component of the population’s diet.  
Salta’s economy is diverse but relatively underdeveloped; poverty is 
a general feature of this society, and there are large socioeconomic inequalities. 
Furthermore, it is a society in which men have a higher employment rate and higher 
positions than women (9). 
We have divided the city into four residential areas defined as: 1) 
slums with housing under deficit conditions, 2) suburbs closest to the city center, 3) 
households located downtown, and 4) residential, wealthy areas.  
 “Deficit conditions” (11) are defined as homes with earthen floors, 
and/or no piped water supply, and/or no sewage system.  
 
1.2.2 Health System 
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Description of the social security model 
According to official data from the 2010 National Census (9), 60% of 
the population of Salta have no healthcare coverage, and are in principle treated in public 
hospitals at no cost, 20% depend on provincial healthcare, 10% depend on a separate 
national retirement healthcare program, 5% depend on a national rural healthcare 
program, and the remaining 5% are affiliated with a public union healthcare system or 
private insurance program.   
Until retirement, patients who are working in a provincial 
government agency are part of the provincial healthcare plan, which covers the cost of 
healthcare expenditure for the patients and their spouse and children. This social security 
program allows free access to public health providers and supports up to 80% of the cost 
at a private institution.   
People working in other public agencies with union affiliation have 
their own healthcare coverage, and they operate in the same way as the state social 
security program. 
The retirement healthcare program is executed only by national 
government appointed healthcare providers.   
Finally, there are private insurance companies, with a high monthly 
cost, allowing free choice of any private health care institution and covering the total 
healthcare expenditure.  
 
Public hospital and private clinics 
The city of Salta has two large public hospitals, one for adults and 
one for obstetrics and pediatrics. In these hospitals, healthcare is at no charge to the 
patients. The hospitals provide comprehensive care in all medical and surgical specialties. 
However, aside from kidney and bone marrow transplants, patients in other transplant 
programs must be referred to other provinces. In Salta, there are also eleven private 
hospitals covering adult medicine.  
For our observational study (12), we have collaborated with one 
public hospital (San Bernardo; responsible for adult medicine), with 450 beds, and eight 
private hospital institutions with a similar number of beds all together. The public hospital 
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and five of the private clinics have cardiac catheterization facilities. Cardiac surgery is 
performed at the public and at two of the private hospitals.    
 










Patients included  by Center 
Patients included  by Center 
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From: http://www.visitingargentina.com/mapas/mapa-politico-argentina.jpg.  















  1.3 Biomarkers 
1.3.1 B-type Natriuretic Peptide (BNP) 
BNP is a counter-regulatory 32-amino-acid neurohormone 
predominantly synthesized in the ventricular myocardium, and is released into circulation 
in response to ventricular dilatation and pressure overload (13, 14). The actions of this 
peptide, like those of atrial (A-type) natriuretic peptide, include natriuresis, vasodilatation, 
inhibition of the renin–angiotensin–aldosterone axis, and inhibition of sympathetic nerve 
activity (15). The plasma level of B-type natriuretic peptide is elevated in patients with 
CHF and increases secondary to, and in relation with, left ventricular dysfunction. After 
acute myocardial infarction (MI), levels of BNP rise rapidly and peak during the first 24 
hours (16-19). BNP also provides prognostic information above and beyond left 
ventricular ejection fraction (LVEF), as well as troponins, in patients with ACS (20-22).  
BNP levels in samples obtained a few days after onset of symptoms 
seem to have superior predictive value as compared to measurements on admission (19-
20). In particular, it is a useful marker for evaluating chest pain or dyspnea, and was 
shown to be helpful in differentiating cardiac and non-cardiac causes of dyspnea. On the 
other hand, it has limited value for initial risk stratification and hence for selecting the 
initial therapeutic strategy in NSTE-ACS (23-24). 
  
1.3.2 High sensitivity C-Reactive Protein (hsCRP) 
Recognizing that atherosclerosis is an inflammatory process, several 
plasma biomarkers of inflammation, such as hsCRP (25), have also been evaluated as 
potential tools for prediction of the risk of coronary events. HsCRP is an acute-phase 
reactant and a marker for underlying systemic inflammation, including atherosclerosis and 
plaque rupture with ensuing thrombus formation (26-31). Through the use of appropriate 
hsCRP assays, it has been possible to investigate the prognostic utility in cardiovascular 
disease (CVD) of plasma CRP levels previously considered to be within the normal range 
(32). Burke and colleagues have suggested that hsCRP in serum reflects the number of 
vulnerable coronary atherosclerotic plaques in sudden cardiac death (SCD) (33).  
In 2009, the Canadian Cardiovascular Society recommended hsCRP 
assessment for patients at “intermediate risk” defined as a predicted risk of a 
cardiovascular event of 10 to 20% over the subsequent 10 years (34). Also in 2009, the 
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National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines 
concluded that measurement of CRP levels might be useful in the stratification of patients 
at intermediate risk for a cardiovascular event, although the evidence for the usefulness of 
measures of fibrinogen and other biomarkers of inflammation was considered to be 
inconclusive (32). A report from the American College of Cardiology Foundation–AHA 
Task Force on Practice Guidelines in 2010 stated that assessment of hsCRP levels is 
reasonable for patients at intermediate risk (35). It is expected that further guidelines 
regarding these biomarkers will emerge, such as the updated guidelines on cholesterol 
(Adult Treatment Panel IV) which are part of the integrated set of guidelines on 
cardiovascular risk reduction from the National Heart, Lung, and Blood Institute (36). 
 
1.3.3 Vitamin D 
It is well known that Vitamin D deficiency in humans is widespread 
and increasing (37). Vitamin D can be ingested or created in the skin on exposure to sun 
and is mostly derived from the latter source. Vitamin D status is commonly assessed by 
determination of 25-hydroxyvitamin D [25(OH)D] in serum which is a common 
denominator for 25(OH)D2 and 25(OH)D3 (38). 
Optimal and exact cut-off levels of 25(OH)D are still under debate. 
The following cut-off levels have been recommended: normal, 75–250 nmol/L, 
insufficiency, 50–74 nmol/L and deficiency, <50 nmol/L (39-40). However, these values 
are based on registry data which do not fully take into account population and 
geographical differences, and factors such as gender and genetics (37). 
Several observational studies and epidemiological data suggest that 
low levels of 25(OH)D may be related to mortality and CVD (41), such as MI (42) and 
SCD (43). 
The general diet does not contain a sufficient amount of vitamin D, 
and without supplementation, we depend on sun exposure to obtain a satisfactory level of 
this vitamin. The cutaneous synthesis of vitamin D is influenced by several factors, 
including geographical location, latitude, altitude, season and daytime, skin colour, age 
and obesity (39, 44-45). 
Fish, the main dietary source of vitamin D, is less preferred by the 
inland and highland beef-consuming population in Northern Argentina, resulting in a 
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lower dietary intake of vitamin D. In our study population from Salta, Argentina, the 
dietary insufficiency of vitamin D may be outweighed by the increased sun exposure 
throughout the entire year at this latitude and altitude. Therefore, we have assumed that 
sun exposure is the essential source for vitamin D synthesis in this population. 
 
1.3.4 Omega-3 Index 
The omega-3 index is defined as the percentage in red blood cell 
(RBC) membranes of EPA and DHA (46), the two most important long chain n-3 fatty 
acids (FA) derived from fish. The index is an independent measure of the amount of n-3 
FA available in the body, reflecting n-3 FA stored in the phospholipid compartment of 
cellular membranes. Although it correlates strongly with measurements made in whole 
blood, plasma and serum (47), its half-life is 4-6 times longer, therefore reflecting the 
average intake over several weeks (48-49). It may thus be a useful surrogate measure of 
the beneficial effects of the omega-3 FA. Epidemiological data suggest that n-3 FA can 
reduce the incidence of CVD (50-53), mainly related to fatal cardiac events. It has also 
been demonstrated that patients with a high tissue ratio of omega-3/omega-6 FA have a 
reduced risk of coronary artery events (54).  
A meta-analysis of randomized trials involving patients with cardiac 
disease showed that supplementation with n-3 FA reduced the rate of death from CHD by 
20% (55). The most significant sources for this study were the GISSI-Prevenzione (56) 
and JELIS trials (57). However, contrary results have been recently published by Rizos et 
al. (58). In this meta-analysis, the authors concluded that omega-3 polyunsaturated fatty 
acids (PUFA) supplementation was not associated with a lower risk of all-cause mortality, 
cardiac death, sudden death, myocardial infarction, or stroke, based on relative and 
absolute measures of association. It is difficult to conclude on the efficacy of n-3 FA 
supplementation based on these studies, as they differ in design, are performed in highly 
different patient populations with different background intake of fish, as well as reflecting 
the administration of a wide range of supplement doses of n-3 PUFA for varying periods 
of time (59). 
Data from randomized and observational studies regarding the effect 
of the n-3 FA on the rate of cardiovascular events in populations with a very low intake of 
fish are currently lacking. N-3 FA display several beneficial cardiovascular properties, 
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such as antiatherothrombogenic, antiarrhythmic, anti-inflammatory and antihypertensive 
effects, and they also lower the triglyceride levels and increase the high-density 
lipoprotein (HDL) levels (59-63). 
Antilipidemic properties are present in populations with a naturally 
high dietary intake of marine n-3 FA (63), but clinical effects in these populations are 




2. AIMS OF THE STUDY 
1. Paper 1:   to assess total mortality, cardiac death and SCD in 
relation to socioeconomic class and social security in patients admitted with suspected 
coronary chest pain living in the city of Salta, Northern Argentina. 
 
2. Paper 2:  to explore the prognostic utility of BNP and hsCRP 
in relation to total- and cardiac mortality within 24 months in a consecutively hospitalized 
patient population with chest pain and suspected ACS. 
 
3. Paper 3:  to assess the prognostic utility of 25(OH)D in 
relation to total mortality, cardiac- and sudden cardiac death in an inland, high-altitude, 
subtropical city in Northern Argentina, characterized by a low dietary intake of fish.  
 
4. Paper 4:  to search for a threshold in relation to mortality 
(total- cardiac- and sudden cardiac death) occurring in a quartile analysis of the omega-3 





3. MATERIAL AND METHODS 
 
3.1 ARgentinean Risk Assessment Registry in the Acute 
Coronary Syndrome (ARRA-RACS) 
This prospective, observational study was a regional multicenter 
prognostic study designed to prospectively evaluate the prognostic impact of 
socioeconomic status and biomarkers including BNP, hsCRP, 25(OH)D and omega-3 
index in a cohort of 982 patients with chest pain and suspected ACS, consecutively 
admitted to nine hospitals in Salta, Argentina from December 2005 to January 2009. Eight 
centers were private and one was public. The public hospital included sixty-two patients, 
representing 6.5 % of the studied population.   
Patients entered into the registry were admitted for ACS as a 
presumptive diagnosis and had to be alive at the time of hospitalization. We used TnT 
levels at baseline and at six hours after admission for disease classification. Furthermore, 
BNP and hs-CRP were determined in all patients as quality indicators in our registry. We 
also measured the serum 25(OH)D content and the omega-3 index in all patients.  
Clinical data were collected at each site by a trained coordinator, 
using a standardized nine-page case report form. Demographic characteristics, medical 
history, presenting symptoms, biochemical and electrocardiographic findings, treatment 
practices, and a variety of hospital outcome data were collected. Monthly intake of fish 
and fish oil supplementation was recorded. 
Recorded information also included patient management data and 
outcome during hospitalization as well as after discharge. The patients received standard 
medical treatment at all centers. However, some patients needed to be referred to other 
more specialized hospitals with cardiac catheterization laboratory facilities when 
intervention was required. 
To be considered eligible for the study, patients had to be at least 18 
years of age at admission and have provided written, informed consent. If the patient 
remained unconscious until death, consent was given by a close family member. The 
exclusion criteria were previous inclusion in the same registry, participation in another 




3.2 Socioeconomic Model 
We divided the total population into three groups based on the 
following variables:  
 The monthly income of the patient or patient’s provider was scored from 1 to 4; 1 
was assigned to those who earned less than 2000 Argentinean pesos a month, 2 to 
those with a monthly income between 2000 - 4000, 3 to those between 4000 - 10000, 
and 4 to those who earned more than 10000 pesos a month.  
 Health insurance, also graded from 1 to 4; 1 was scored by subjects without insurance 
coverage, 2 by subjects on a retirement social health program, 3 by state employees 
and union associated employees, and 4 by patients with private health insurance.  
 Residential area was graded from 1 to 4 according to the patient’s housing conditions 
defined according to location, ranging from poor to wealthy areas, as previously 
defined.  
We added the grading of each variable, obtaining a socioeconomic level for each subject 
and according to this level they were divided into three categories; low social class (3-5 
points), middle class (6-8 points) and upper class (9-12 points). Accordingly, 147 out of 
155 individuals without social security were found in the first category, whereas all 
subjects in the third belonged to a social healthcare program. Occupation/employment 
was not included as an individual variable in this socioeconomic model, as it is related to 
income in this community. 
 
            3.3 Ethics Statement 
The study was approved by the Ethics Committee of the Board of the 
Medical School of Salta and conducted in accordance with the Helsinki Declaration of 
1971, as revised in 1983. At San Bernardo Hospital and Sanatorio El Carmen, the study 
was also approved by the local Ethics Committee and Institutional Review Board. The 
Norwegian bio-bank containing Argentinean blood samples was approved by the 
Regional Board of Research Ethics and the Norwegian health authorities. The study was 
monitored by Stavanger Health Research, Stavanger, Norway. Written informed consent 




3.4 Outcome and Follow-up 
The primary outcome measure of the present study was all-cause 
mortality from the time of inclusion up to five year follow-up. The secondary outcome 
was cardiac death, including sudden cardiac death. The term ACS in the present study 
encompasses UAP, NSTEMI and STEMI. The following classification for the index 
diagnosis was used: STEMI; ST-segment elevation combined with TnT values > 0.03 
ng/mL. NSTEMI; Transient ST-segment elevation, ST-segment depression, or T-wave 
inversion in at least 2 contiguous leads combined with TnT values > 0.03 ng/mL. UAP; 
Transient ST-segment depression or T-wave inversion and TnT values ≤ 0.03 ng/mL, or 
borderline TnT values above 0.01 ng/mL up to 0.03 ng/mL without ECG changes. No-
ACS: All other conditions (i.e. unspecific chest pain, arrhythmias, atrial fibrillation etc.) 
without ECG changes and with negative troponins.  
The definition of cardiac death included death, preceded by a 
definitive MI or by chest pain > 20 minutes without a given TnT, or a history of ischemic 
heart disease and no other obvious cause of death (64).   
SCD is defined as unexpected death due to a cardiac cause occurring 
within one hour of symptom onset or as a witnessed unexpected death (65).  
Outcome including survival status, date and cause of death were 
obtained from hospital records, close family members and a link to municipal and 
provincial registries (Civil Registry of the Province of Salta) at regular intervals; 30 days, 
6 months and annually during the 5-year follow-up period. A personal interview by a 
physician was performed one year from index admission. An endpoint analysis at 2 years 
was also recorded.  
 
           3.5 Blood and Chemical Analysis 
Peripheral blood samples for determination of TnT, creatinine, 
glucose, lipids and hsCRP in serum and BNP in ethylene diamine tetraacetic acid (EDTA) 
plasma were drawn immediately following admission by direct venipuncture of an 
antecubital vein, applying a minimum of stasis. A repeated blood sample for the second 
determination of TnT was drawn six hours following the primary blood sample. Clotted 
whole blood and EDTA blood samples were centrifuged for 15 min with 2000 x g at 20°C 
without delay. Serum and EDTA plasma were immediately frozen in three aliquots, stored 
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locally at -70°C and transferred in frozen condition (dry ice) to Stavanger, Norway in 
three different shipments, the first after collection of 100 samples, the next containing 400 
samples, and remaining samples in a third shipment. These samples were stored in a 
Norwegian bio-bank at -70°C until measurements were performed. 
TnT was quantified by a cardiac-specific second-generation TnT 
ELISA assay from Roche diagnostics, using a high-affinity cardiac-specific TnT isoform 
antibody (66). The lower detection limit of the assay used was 0.01 ng/mL. In this study a 
cut off level of 0.01 ng/mL was therefore used with a coefficient of variation (CV) of 
10%. 
BNP was analysed in EDTA plasma using the Microparticle Enzyme 
Immunoassay (MEIA) Abbott AxSYM® (Abbott Laboratories, Abbott Park, Illinois, 
USA). The dynamic range was 0-4000 pg/mL and the within-run coefficient of variation 
(CV) was 6.3% at 95 pg/mL and 4.7% at 1587 pg/mL, respectively. 
Hs-CRP was measured with the use of an immunoturbidimetric assay 
(Tina-quant® C-reactive protein (latex) high sensitive assay, Roche Diagnostics, 
Germany) performed on a Roche automated clinical chemistry analyzer (MODULAR P). 
The detection limit was 0.03 mg/L and the measuring range 0.1-20.0 mg/L with an 
extended measuring range with automatic re-run of 0.1-300 mg/L. The between-assay CV 
was 3.45% at 1.19 mg/L and 2.70% at 0.43 mg/L, respectively. 
 
3.5.1 Vitamin D  
Assessment of vitamin D status was performed by determination of 
the metabolites 25(OH)D3 and 25(OH)D2 in serum by liquid-liquid extraction (LLE), 
derivatization with 4-phenyl-1,2,4-triazoline-3,5-dione reagent (PTAD, Sigma-Aldrich, 
St. Louis, MO, USA), and analysis by liquid chromatography coupled with tandem mass 
spectrometry detection (LC-MS/MS). A one-step LLE procedure was performed by 
mixing 50 μl serum, 50 μl internal standard solution, comprising 160 ng/ml of 6-
deuterium labeled 25(OH)D3 (Synthetica, Oslo, Norway) in isopropanol, 350 μl of 200 
mmol/L magnesium sulphate, and finally 900 μl acetone and heptane (1+1). The upper 
heptane layer was acquired and evaporated, followed by addition of 100 μl of 0.5 mg/ml 
PTAD reagent in dry acetonitrile. The LC-MS/MS analysis was performed with an 
Acquity UPLC coupled with a Quattro Micro (Waters, Milford Massachusetts, USA). The 
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separation was isocratic, using a 2.1×50 mm Acquity BEH C18 UPLC column (Waters) 
and a 0.5 mL/min mobile phase flow consisting of 20% ammonium hydroxide (0.1%) and 
80% acetonitrile. Tandem mass spectrometry detection was with positive electrospray 
ionization (ESI+), using 3 kV and 30 V for capillary and cone voltage, respectively. 
Collision energies were 15 eV for 25(OH)D3 and 17 eV for 25(OH)D2. The multiple 
reaction monitoring transitions (molecular ion > fragment ion, monoisotopic molecular 
weight in Da) were 558.5>298.2 for 25(OH)D3, 564.5>298.2 for deuterium labeled 
25(OH)D3, and 570.5>298.2 for 25(OH)D2. 
Calibration of the linear relationship between peak area response 
ratio relative to sample concentration of 25(OH)D3 and 25(OH)D2 was achieved by using 
serum calibrator #38033 (Chromsystems, Munich, Germany). Within each microwell 
plate, the analytical quality was monitored by analysis of 5 different control samples: 
#0029 and #0030 (Chromsystems), #35080 and #35081 (Recipe, Munich, Germany), and 
HK10 (DEKS, Herlev, Denmark). The CV for the control samples analyzed over 25 series 
were in the range of 8.7–10.8% for 25(OH)D3 and in the range of 10.7–16.5% for 
25(OH)D2. Intra-series repeatability was estimated at three different levels, and the CV’s 
found were in the range of 2.9–8.2%. Method bias was estimated by relative difference 
from the quality control sample values. For 25(OH)D3, 21–22% bias was found by 
analysis of control samples with reference values of 38.6 and 59 nmol/L, and 1–2% bias 
was found for samples with reference values of 73.4 and 136 nmol/L. For a control 
sample with a high reference value of 265 nmol/L, the bias was −18%. For 25(OH)D2, the 
control samples with reference values of 39, 62 and 126 nmol/L, respectively, were 
associated with biases in the range − 3 – 8 %. Finally, a bias of – 9 % was found for a 
sample with a high reference value of 252 nmol/L. 
 
3.5.2 Omega-3 Index 
The RBCs were prepared as follows: After removing the plasma from 
the EDTA blood solution following centrifugation, the RBCs were washed once with 5 
mL of 0.9% saline solution and then centrifuged at 1800 rpm for 8 min. The sediment 
containing the RBCs was stored in two tubes at -70°C after temporary storage at -20°C for 
1 to 14 days. All RBCs samples were transferred on dry ice in one shipment to VITAS 
laboratories, Oslo, Norway, for measurement of FA. Frozen RBC samples were thawed 
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overnight in a refrigerator. Approximately 40 μL of wet RBCs were transferred to a 1.8 
mL GC vial using a pipette with a wide opening. After a 3 second vortex mix, 900 μL 3N 
methanolic HCl was added followed by another 3 second vortex mix and capping of the 
vial. Vials were then incubated at +80°C with mixing at 1000 rpm for 2 hours. The vials 
were cooled to room temperature and 500 μL hexane and 300 μL 3M KOH in water were 
gently added. After capping, shaking for 5 min and centrifuging for 5 min at 4000 rpm, 1 
μL was injected by pulsed split less injection on a GC-FID system (Agilent G7890A, 
Agilent Technologies, Waldbronn, Germany). Separation was performed on a SP-2380 
(30 m x 0.25 mm i.d. x 0.25 μm film thickness) column from Supelco, USA. The 
following temperature program was used: initial temperature of 90 °C held for 0.5 min, 
then increased by 50 °C/min to 150 °C, then increased by 10 °C/min to 225 °C, then 
increased by 120 °C/min to 245 ° C and held for 3 min. The oven was cooled before the 
next injection. FA were identified by comparison with known standards. An external 
standard containing known amounts of relevant FAME (fatty acid methyl esters) (Supelco 
37 component FAME Mix, Supelco Bellafonte, USA) was included in each run to correct 
for differences in FA response factors. The individual FA was reported as a weight 
percentage of the total FAME and the omega-3 index was given by the sum of EPA and 
DHA. The inter-assay coefficient of variation was 4%. To adjust to the analysis 
previously employed in a similar study performed in the southwestern coastal region of 
Norway (67), C22:0, C24:0, C24:1, and unidentified peaks were removed from the 
denominator prior to the calculation of weight percentage. The arachidonic acid 
(AA)/EPA + DHA ratio was based on the unadjusted values and introduced to reflect the 
balance between omega-6 and omega-3 in a nutritional perspective. 
We analyzed 980 out of 982 RBC samples; one sample was missing 
and another was coagulated. 408 samples displayed signs of oxidation, leaving 572 
patients available for the present evaluation. By oxidation, we mean that the 
concentrations of the easily oxidizable PUFA were not normally distributed as for other 
FA, but showed a second distribution, severely skewed towards very low concentrations, 
and superimposed on the expected normal distribution for docosapentaenoic acid (DPA). 
This strongly suggests degradation, with PUFA concentrations approaching zero in some 
samples. In order to discriminate between oxidized and non-oxidized samples we applied 
a k-means cluster analysis (SPSS 19.0, SPSS Inc. Chicago, IL, USA), by which we 
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divided the material into 2 groups with respect to C22:6,n-3 (DHA), C22:5,n-3 (DPA), 
C20:5,n-3 (EPA), C22:4,n-6, C20:4,n-6 and C20:3,n-6. By taking all these FA into 
consideration in combination, the cluster analysis may be regarded as more objective and 
powerful as compared to the evaluation of only one of these FA with respect to oxidation. 
The cluster analysis placed samples from 408 subjects in the oxidized group and samples 
from 572 patients in the non-oxidized group with a normal distribution of PUFA. 
 
3.6 Statistics  
The patients were divided into quartiles according to their BNP, 
hsCRP, 25(OH)D and their adjusted omega-3 index levels. Approximately normally 
distributed variables were given as mean and standard deviation (SD), whereas variables 
with skewed distributions were given as median and quartiles. The Chi-square test for 
association was applied between the BNP, hsCRP, 25(OH)D and omega-3 index quartiles 
and categorical variables at baseline. The one-way ANOVA test was used to test for 
equality of means of scale variables (i.e. age) amongst quartiles, and the two-sample t test 
and Mann-Whitney test were used for comparing the means and medians of two samples, 
respectively. The hazard ratios (HR) are presented with 95% confidence interval (CI). 
Stepwise Cox multivariable proportional hazards regression models with total-, cardiac- 
and sudden cardiac death as the dependent variables and BNP, hsCRP, 25(OH)D and 
omega-3 index quartiles and other variables as potential independent predictors were 
fitted. To examine the differences in prognosis between subjects in the upper versus the 
lowest quartile of BNP, hsCRP, 25(OH)D and omega-3 index we adjusted for age, sex, 
smoking, hypertension, index diagnosis, creatinine/estimated glomerular filtration rate 
(eGFR), [calculated by Modification in Diet in Renal Disease (MDRD) formula], DM, 
body mass index (BMI) (kg/m2), CHF (defined by Killip-Kimball class at admission, 
those patients in class 2 to 4 were classified as CHF patients and class 1 as non-CHF), 
history of previous CHD (i.e. history of either angina pectoris, MI, coronary artery 
bypass graft (CABG), or percutaneous coronary intervention (PCI), 
hypercholesterolemia/use of statins, BNP, hsCRP, 25(OH)D and adjusted omega-3 index 
quartiles, triglycerides, HDL cholesterol, systolic and diastolic blood pressure, TnT > 
0.01 ng/mL and beta-blockers prior to enrolment. Kaplan-Meier product limits were used 
for plotting the times to event, with the survival curves assessed by the log-rank test. In 
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the discriminate analyses BNP, hsCRP, 25(OH)D, omega-3 index and their natural 
logarithm were used as individual variables. The statistical analyses were performed 
using the statistical package SPSS version 19.0. All tests were two-sided with a 
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5. SUMMARY OF RESULTS 
1. Paper 1 
After a follow-up period of 5 years, 173 patients (17.6%) had died. In 
92 patients (9.4%) death was defined as cardiac, of which 59 patients (6.0%) were 
characterized as SCD. In the multivariate analysis, the HRs for all-cause mortality and 
cardiac death in the highest socioeconomic class as compared to the lowest was 0.42 (95% 
CI, 0.22 - 0.80), p = 0.008 and 0.39 (95% CI, 0.15 - 0.99), p = 0.047, respectively, whereas 
the results were not significant for SCD.  
Comparing patients in the upper socioeconomic class, in which all 
individuals had a social security program, to patients without healthcare coverage, the 
multivariate analysis demonstrated an improved outcome with respect to total mortality, as 
well as a borderline difference suggesting improved survival with respect to cardiac death, 
in patients with health coverage. The HRs were 0.46 (95% CI, 0.23 - 0.94), p = 0.032 and 
0.37 (0.14 - 1.01), p = 0.054, respectively, whereas no difference was noted for SCD. 
However, in the TnT positive patients a similar but significant relationship was found for 
both total- and cardiac death. 
After extracting patients without healthcare coverage, total mortality 
and SCD still remained lower in the upper socioeconomic class as compared to the lowest 
class, with HRs of 0.42 (95% CI, 0.22 - 0.81), p = 0.009 and 0.30 (95% CI, 0.10 - 0.93), p = 
0.037, respectively. No difference was found in relation to cardiac death. 
 
2. Paper 2 
The median BNP and hs-CRP concentrations in plasma were 78.1 
(35.8 - 179.7) pg/mL [25 and 75% percentiles] and 3.1 (1.3 - 8.4) mg/L [25 and 75% 
percentiles], respectively.  
In the univariate discriminate analyses, a TnT positive event at 
admission was correctly classified by BNP in 66.7% and by hsCRP in 64.2% of cases in 
their non-logarithmic form and slightly less in their logarithmic form. The specificity of 
non-logarithmic BNP and hsCRP for predicting all-cause mortality in the total population 
was 89.6% and 90.3%, respectively, with a sensitivity of 44.5% and 31.9%, respectively. 
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Combining the two predictors in our quartile comparisons did not 
increase the prognostic impact as compared to the separate analysis of BNP and hsCRP. 
 
All-Cause Mortality 
After a follow-up period of 24 months, 119 patients (12.2%) had 
died. The BNP and hsCRP levels were significantly higher among patients dying than in 2-
year survivors; 228 (66 - 603) versus 72 (34 - 148) pq/mL [median, 25 and 75% 
percentiles], p = 0.000 and 7.8 (2.3 - 35.6) versus 2.9 (1.3 - 7.5) mg/L [median, 25 and 75% 
percentiles], p = 0.000, respectively.  
In a stepwise multivariate Cox regression model, BNP was found to 
be a prognostic indicator of 2 year total mortality in the total patient population. The HR for 
BNP in the highest quartile (Q4) was 2.32 (95% CI, 1.24 - 4.35) as compared to the lowest 
quartile (Q1), which was statistically highly significant, p = 0.009. In the multivariate Cox 
regression model hsCRP levels also showed a significant relation to prognosis, with a HR 
of 1.97 (95% CI, 1.17 - 3.32), p = 0.011. 
The area under the curve (AUC) for the receiver operator 
characteristics (ROC) for BNP, hsCRP and TNT was 0.711 (p = 0.000), 0.666 (p = 0.000) 
and 0.666 (p = 0.000), respectively. 
 
Cardiac Death 
After a follow-up period of 24 months, 66 patients (6.9%) had 
experienced cardiac death. 
In the univariate analysis for the total population, the HRs for BNP 
and hsCRP were 6.97 (95% CI, 2.94 - 16.54), p = 0.000 and 2.25 (95% CI, 1.19 - 4.28), p = 
0.013, respectively. In a stepwise multivariable Cox regression model, the HR for BNP was 
3.34 (95% CI 1.26 - 8.85), p = 0.015, whereas the HR for hsCRP was not significant, p = 
0.21.  
Including patients with borderline troponin levels ≤ 0.05 ng/mL 
among the TnT negative patients and without adjusting for a positive troponin value, the 
HR of BNP for cardiac death in Q4 as compared to Q1 in the multivariate Cox regression 
model was 3.58 (95% CI, 1.02 - 12.60), p = 0.047, in this extended patient category. The 




3. Paper 3 
A significantly higher proportion of patients dying was found in Q1 
of 25(OH)D as compared to Q4, both in the total population (25.3% vs 6.1%) and in 
patients with a TnT release, (43.3% vs 9.3%) each p < 0.0001, respectively. 
The specificity of non-logarithmic 25(OH)D for predicting all-cause 
mortality in the total population was 62.2%, with a sensitivity of 67.2%.  
When comparing 25(OH)D in Q4 to Q1 in a multivariable Cox 
regression model for all-cause mortality within 2 years in the total patient population, the 
HR was 0.37 (95% CI, 0.19 - 0.73), p = 0.004. For cardiac death, the HR was 0.23 (95% 
CI, 0.08 - 0.67), p =0.007, and for SCD the HR was 0.32 (95% CI, 0.11 - 0.94), p= 0.038. 
 
Patients with troponin T release 
When comparing 25(OH)D in Q4 to Q1 in a multivariable Cox 
regression model for all-cause mortality within 2 years in patients with TnT release, the HR 
was 0.24 (95% CI, 0.10 - 0.54), p = 0.001. For cardiac death, the HR was 0.18 (95% CI, 
0.05 - 0.60), p = 0.006, and for SCD, the HR was 0.25 (95% CI, 0.07 - 0.89), p = 0.033. 
The area under the ROC curve for 25(OH)D was 0.276 (p < 0.0001). 
 
Patients without troponin T release 
After a follow-up period of 24 months, 37 patients (6.3%) of 593 
with no TnT release had died. In the univariate analysis of all-cause mortality in these 
patients, the HR for 25(OH)D was 0.39 (95% CI, 0.15 - 1.00), p = 0.05, whereas 25(OH)D 
status did not add any prognostic information related to cardiac death and SCD. 
 
4. Paper 4 
In our main analysis, we disregarded approximately 40% of the RBC 
samples due to the presence of oxidation. In the 572 patients with non-oxidized samples, 
the mean(SD)% value of AA (C20:4,n-6) was 11.82(1.80)%, whereas the mean(SD)% of 
EPA, DHA, and DPA were 0.25(0.09)%, 2.57(0.74)%, and 1.65(0.37)%, respectively. The 
mean(SD)% of the omega-3 index was 2.81(0.79)%. After adjusting for C22:0, C24:0, 
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C24:1, and unidentified peaks, the mean (SD)% of the omega-3 index increased to 
3.58(0.99)%.  
Patients were followed for a median period of 3.6 years, range 1 day 
to 5.5 years.  At final follow-up, 100 patients (17.5%) had died. The rate of death was 
found to be similar in all quartiles of the AA/EPA + DHA ratio, and the prognostic utility 
was not improved by looking separately at the adjusted omega-3 index. In the multivariable 
model for the five year follow-up data, HR (95% CI) for each of the three upper adjusted 
omega-3 index quartiles as compared to Q1 were non-significant; Q2: 0.89 (0.48 - 1.65), 
Q3: 0.80 (0.43 - 1.50), Q4: 0.73 (0.38 - 1.42), respectively. Only age, TnT > 0.01, level of 
creatinine, hsCRP quartiles, and systolic blood pressure at admission predicted total 
mortality. 
Cardiac death and SCD 
At final follow-up, cardiac death occurred in 54 (9.4%) patients, of 
whom 35 (6.1%) were classified as SCD. For the endpoints of cardiac death and SCD there 
were no significant reductions across quartiles. In the multivariate model for cardiac death, 
the HR (95% CI) in each of the three upper as compared to Q1 of the adjusted omega-3 






     6.1 Paper 1  
A large proportion of the Argentinean population is not covered by 
social security programs. For example, in the city of Salta, 60% have no coverage. In this 
prospective observational study, 15.8% of the admitted patients were not covered by a 
social security program, which is mainly due to major recruitment at the private clinics. 
Although the public hospital is equipped with a similar number of patient beds as all the 
private clinics together, it only made up 6.5% of the patient population. Comparing the 
upper socioeconomic class to patients without a social security program in our 
multivariate analysis, in which age, gender, hypertension, DM type 2 and BNP were 
corrected for, a similar relationship was found for both total- and cardiac mortality, 
suggesting that the lower socioeconomic group was worse off, irrespective of a social 
security program. Thus, in our study we found that socioeconomic inequalities are of 
greater importance for survival than having social security coverage.  
In our multivariate analysis, total- and cardiac mortality was elevated 
in the TnT positive patients belonging to the low socioeconomic class, whereas survival 
was unaffected by socioeconomic grouping in the TnT negative population. This would 
suggest that the lower socioeconomic group may have received less medical attention 
following the index event.  In the Copenhagen Male Study, the authors suggest that 
potential modifiable risk factors associated with life style and working environment are 
strong mediators of social inequalities in risk of ischemic heart disease (68). In the Salta 
region there is a high rate of unemployment and a large proportion of the workers are not 
protected by union rights, which may have an unfavourable effect on daily life, affecting 
individual health conditions.  
In the Scottish Heart Health Study it was shown that prevalent (69) 
and incident CHD (70,71) is related to housing tenure status (owner – occupiers or 
renters), regarded as a sensitive measure of social class, as house renting was 
predominantly a feature of the socially disadvantaged. In the lower socioeconomic class 
in our study, it is mainly the living conditions and not the possession of property that is 
influencing CHD mortality.   
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In a study based on socioeconomic inequalities in 22 European 
countries, access to health care was found to be one of several factors associated with 
inequality (72). Our findings of increased mortality in the lower socioeconomic class and 
among individuals without a social security program are in accordance with this 
statement.  
An inverse relationship between education and mortality has also 
been reported (73). We did not include education in our socioeconomic model, as our 
study was not related to primary prevention, but was based on a population with suspected 
and documented coronary heart disease; education was not regarded as an essential 
mediator of health in this population. Furthermore, a primary prevention study performed 
in Brazil (74) concludes that there is an inverse relationship between cardiovascular 
mortality and income, education and poor housing conditions. However, that was a 
primary prevention study with univariate data, in contrast to our study, in which data have 
been provided in a secondary prevention setting, correcting for potential confounders. 
In contrast to Argentina, nations with a social democratic healthcare 
system provide all inhabitants with a similar social security program, and thus the same 
level of medical attention irrespective of income. In these populations health will largely 
depend on other factors, such as education and employment. Thus, in a system with an 
egalitarian social security program, primary and secondary prevention is the key to better 
health, whereas in a system in which 60% of inhabitants have no social security, a lack of 
medical attention may largely explain the increase in cardiac mortality. 
 
     6.1.1 Limitations 
Foremost among the limitations inherent to our study is the relatively 
small sample size (n = 982) compared to larger studies. Furthermore, the present study 
includes patients from one Argentinean city, and therefore only represents the 
demographics of the city of Salta, located in Northern Argentina. Our results do not 
necessarily represent other provinces in Argentina and should not be extrapolated to other 
countries. Most of our patients were included at private centers, and as only 15.8% of the 
expected 60% had no social security coverage, this population is highly selected. 
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6.2 Paper 2 
The present study was carefully designed to meet the requirements 
for a prognostic evaluation of biomarkers. Contrary to randomized studies, patients are 
unselected and included on a consecutive basis, which offers a great advantage for risk 
identification. In this study, we have included admission samples of the two biomarkers 
BNP and hsCRP to investigate their impact on prognosis in patients with chest pain and 
suspected ACS. We have discriminated between patients with and without a release of 
TnT. In the stepwise multivariate model applied to the total patient material, which 
included both the presence and absence of TnT release, we were able to demonstrate a 
statistically significant prognostic impact of BNP and hsCRP on 2-year survival, both for 
total- and cardiac mortality. In the TnT positive subgroup we found that BNP had a 
statistically significant prognostic impact in the stepwise multivariate Cox regression 
model on all-cause mortality and cardiac mortality. On the other hand, hsCRP was found 
to be related only to total mortality.  
In a univariate discriminant analysis we found that a TnT positive 
event was correctly classified by BNP or hsCRP in over 60% of cases. The specificity of 
BNP and hsCRP for predicting all-cause mortality in the total population was around 90% 
for both biomarkers, associated with sensitivities of 44.5 and 31.9%, respectively. In the 
present study, patients in the highest quartile for both BNP and hsCRP were older than in 
the remaining quartiles, and a higher proportion had TnT exceeding 0.01 ng/ml. In the 
highest quartile of BNP there were also more past smokers and subjects with established 
CHD and HF, and creatinine was elevated. These differences reflect the increased burden 
of risk in the upper quartiles of BNP and hsCRP, respectively. Despite some similarities 
in underlying risk burden, these two predictors are mechanistically different. However, 
their combinations were not found to strengthen the prognostic utility.  
Our results indicate that both BNP and hsCRP are major predictors of 
outcome in a population for which invasive coronary intervention is less available as 
compared to wealthier communities. Indeed, only 29% of the total population and 38% of 
the TnT positive population underwent a revascularization procedure during the 
hospitalization for the index event. Thirty-one percent of the TnT positive population was 
classified as STEMIs, and of these patients only 42% were treated with primary PCI. 
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Furthermore, the use of thrombolytic therapy in this region of Argentina is uncommon 
and was not applied in our patient cohort. The infrequent use of reperfusion treatment in 
STEMI patients makes the study population unique in an epidemiological setting, 
optimizing the evaluation of prognostic indicators in relation to the natural course of 
disease.  
As mentioned previously, the prognostic utilities of BNP and hsCRP 
remained statistically significant with respect to total mortality in both the total population 
and in TnT positive patients.  It has been known since the mid 90’s that elevated troponins 
are associated with a worsened prognosis in ACS patients (75), and that its prognostic 
utility exceeds that of all other biomarkers, including BNP (17) and hsCRP (31). 
Nonetheless, based on previous studies (18,19,76) addressing hsCRP, this biomarker has 
been considered for adoption into risk assessment algorithms (77). Recently conducted 
studies have, however, shown that the predictivity of hsCRP is attenuated when tested in a 
multivariable model in the general population (78), and together with natriuretic peptides 
in patients with known CAD (79-82). In our study, hsCRP appears to be a potential 
predictor for all-cause mortality, also when adjusted for BNP, but does not reflect cardiac 
mortality in the TnT positive population when introducing BNP into the model. The main 
prognostic impact of BNP was found in the TnT positive patients, suggesting a relation to 
ischemia.  
In contrast to the majority of previous studies investigating the 
prognostic impact of various biomarkers, our study had a prospective and observational 
design, and blood samples were collected directly on admission. Few studies have 
examined the predictive value of natriuretic peptides across the spectrum of chest pain 
patients with suspected ACS in blood samples obtained on admission, before introduction 
of therapy. Therefore, as in a related study (83), we do not have to consider the potential 
confounding factors of late inclusions and recently introduced medical treatment in the 
present study. Similar considerations apply to the measurement of hsCRP. A major 
strength of our study is the absence of patients lost to follow-up; in fact, there were only 
four patients with no measurements available for hsCRP. Moreover, our study was 
performed in an inhomogeneous and unselected chest pain population with suspected 
ACS, which is representative of the one commonly dealt with in the emergency 
department. Our study suggests that BNP and/or hsCRP in addition to the troponins may 
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be supplementary biomarkers in risk stratification. However, their impact in the clinical 
prognostic assessment of ACS patients depends on the presence of troponin release.  
 
6.2.1 Limitations 
The potential limitations of our study merit consideration. The 
circulating concentrations of BNP and hsCRP prior to hospitalization remain unknown 
and our analyses are based on a single baseline determination. Although we did not adjust 
for LVEF, we did adjust for known CHF and CVD, including previous MI, and other 
clinical risk factors. 
 
6.3 Paper 3 
This prospective observational study was designed to evaluate the 
prognostic utility of 25(OH)D in admission samples from consecutively included chest 
pain patients with suspected ACS in a beef-eating population living at a high altitude in a 
subtropical inland city of Argentina. We performed a comparative interquartile analysis of 
25(OH)D as a prognostic biomarker in the total patient population, and in subgroups with 
and without TnT release, respectively. After correcting for other possible confounders 
including cardiovascular risk factors, we were able to demonstrate a statistically 
significant association between reduced levels of 25(OH)D and 2-year survival , including 
cardiac death and SCD, both in the total population and in patients with a TnT release.  
Several other observational and epidemiological studies have also 
shown an inverse association between both all-cause and cardiac mortality and vitamin D. 
In the NHANSE III study, the lowest 25(OH)D quartile was associated with a higher risk 
of all-cause mortality in the general US population (84) as well as in older US adults (age 
>65) (85). In the general US population, the CVD mortality showed a similar trend, but 
did not remain statistically significant in the fully adjusted model, whereas CVD mortality 
was found to be statistically significant in the older US population. The Tromsø study 
(86) showed a significantly increased risk of all-cause death in the lowest 25(OH)D 
quartile as compared to the highest in the non-smoking population, but did not predict 
CVD outcome. Furthermore, low levels of 25(OH)D were associated with all-cause and 
cardiovascular mortality in the LURIC study (87), which included clinically stable 
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patients referred for coronary angiography. In the Nurses’ Health Study and the Health 
Professionals Follow-Up Study (88) it was suggested that a higher vitamin D intake 
correlated with a lower risk of CVD in men, but not in women. In the Mini-Finland 
Health Survey, Kilkkinen et al. (41) demonstrated that a low level of 25(OH)D may be 
associated with a higher risk of a fatal CVD event. Finally, two other studies suggested a 
higher prevalence of 25(OH)D deficiencies in patients with acute MI (42,89). 
In our study, patients were recruited from a subtropical area at an 
altitude above 1000 m and included a predominantly Hispanic population. Despite the 
geographical location there were significant seasonal changes in 25(OH)D levels. The 
dietary contribution of vitamin D is probably negligible in this population as the intake of 
fatty fish, the primary source of vitamin D, is very low. Also, food fortification with 
vitamin D in Argentina was only introduced at the end of 2010. Despite the availability of 
vitamin D through sun exposure, a high proportion of the population demonstrated 
subnormal levels of 25(OH)D, which could be explained by a lifestyle with long working 
hours and a siesta in the middle of the day to avoid the heat of the sun. Furthermore, the 
majority of the population belonged to an urban and sheltered environment. Although the 
patients were living at a moderate altitude, it is insufficient to promote noteworthy 
additional exposure to UV radiation.  
In both the univariate and multivariate analyses, we demonstrated a 
statistically highly significant increase in all-cause mortality, cardiac and SCD in Q1 as 
compared to Q4, both in the total patient population and in patients with TnT release. 
After adjusting for covariates, the prognostic utility of 25(OH)D was maintained for all 
end-points. ROC analysis supports our results related to low 25(OH)D values and high 
mortality in the total population (AUC 0.307, 95% CI [0.254 - 0.361], p = 0.000) and in 
the population with TnT release (AUC 0.276, 95% CI [0.213 - 0.339], p = 0.000). 
A strength of this study is the inclusion of patients with suspected 
ACS, collection of blood samples at admission, a planned sub-group analysis according to 
TnT release and a prospective design, evaluating the prognostic value of 25(OH)D in 
relation to pre-specified endpoints consisting of total mortality, cardiac and sudden 





Concentrations of 25(OH)D in the healthy state prior to 
hospitalization remain unknown, and our analyses are based on a single baseline 
measurement. As patients in our ACS registry were strictly treated according to ACC 
guidelines, medication was not recorded specifically post-discharge. Differentiation of 
chest pain was usually performed prior to hospitalization and our patients were included 
after admission with a suspected ACS diagnosis. Although we did not adjust for LVEF, 
we did adjust for BNP and known CHF (Killip-Kimball class). Finally, we did not correct 
for parathyroid hormone. 
 
             6.4 Paper 4 
In this paper, we assessed the prognostic utility of the omega-3 index 
in patients admitted with acute chest pain and suspected ACS, grouping the patients 
according to quartiles of the omega-3 index. After adjustment for potential confounders, 
there were no significant differences in the risk of all-cause mortality, cardiac death, or 
SCD between quartiles of the omega-3 index. No additional prognostic information was 
obtained by introducing the ratio between AA and omega-3 index. In contrast to this 
result, Von Schacky and Harris (47) previously demonstrated that an omega-3 index >8% 
is associated with 90% less risk for SCD, as compared to an omega-3 index of <4%. A 
retrospective case-control study from the US in ACS patients furthermore supported this 
proposed cut-off point (90).  Our results are, however, in accordance with the results 
obtained in a coastal Norwegian chest-pain population (67).  
An ingestion of omega-3 falling short of the aforementioned 
threshold may explain the results from studies demonstrating lack (63,91) or less benefit 
than expected (57) of omega-3 supplementation. Therefore, we designed the present study 
to search for a threshold related to mortality in a quartile analysis of the omega-3 index in 
a chest pain population with a low intake of omega-3 FA. We found no evidence of a 
threshold related to a worse outcome within the range of the adjusted omega-3 index. The 
median adjusted omega-3 index in the lowest as compared to the highest quartile was 
2.5% and 4.8%, respectively, and an index level above 4% appeared to offer no 
cardiovascular protection. The low levels of the omega-3 index in our study population 
may be explained by the predominance of meat in the local diet. Indeed, the assumption 
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of a possible threshold related to clinical benefits of omega-3 FA is mainly based on 
studies (92) of populations characterized by a considerably higher intake of omega-3 than 
in the present study. As we did not observe a decline in SCD within our omega-3 index 
quartiles, we presume that their anti-arrhythmic effect is not expressed in secondary 
prevention following ACS in a population with a very low intake of omega-3 FA.  
The median of 4.8% in the upper quartile of the omega-3 index in the 
present study population is comparable to the median of 4.7% in the lowest quartile of the 
previously reported chest pain population from coastal Norway (67). As such, we had 
expected that the Argentineans would display omega-3 levels below the protective anti-
arrhythmic threshold of the omega-3 FA. There was no gradient related to SCD risk 
through the quartiles of the omega-3 index, irrespective of TnT release during the index 
event, suggesting that levels higher than 4% of the omega-3 index are needed for anti-
arrhythmic protection. There may be other factors required to yield a beneficial effect 
from omega-3 FA.  
 
6.4.1 Limitations  
Although oxidation was found to be present in approximately 40% of 
the total population, the remaining 60% were regarded as reliable, with a level of DPA 
(not included in the omega-3 index) approaching that of the Norwegian population in 
which the HS-Omega-3 index® was measured (93). Furthermore, in our Argentinean 
population, the mean (and median) level of unadjusted AA was 12% of total FA, far 
higher than our patient groups in coastal Norway, reflecting a high intake of meat. AA is 
also highly oxidizable, and its relative percentage supports the quality of our 
measurements. The loss of 40% of the total patient population may have introduced a bias 
in the interpretation of our results, but, fortunately, the baseline characteristics of patients 
with and without the presence of oxidation were found to be similar, supporting our 
conclusions. As the total patient sample was reduced due to the oxidation phenomenon, 
42.2% of total deaths were also lost, which has decreased the statistical power of our 
study. We must emphasize that we have only studied the utility of the omega-3 index as a 
biomarker for future all-cause and cardiac death, and that our results should not be 




              6.5 General limitations 
Weaknesses of all of the above studies include the relatively small 
sample size (n = 982, and n = 572 for Paper 4) compared with larger studies. Furthermore, 
our work included patients from only one Argentinean city; thus, the generalizability of 
the results to other cities, provinces, communities, and countries is uncertain. We could 
also not establish the time from symptoms onset to treatment in all patients.  
This is not a randomized study, but a prospective, observational study 
with only few exclusion criteria limited to age, consent and prior inclusion, and all ACS 
patients who were asked to participate, accepted the invitation, except for two subjects. 
We cannot provide the exact number of patients who were not asked. However, in the 
private hospitals from which 93.7% of the study population was sourced, the admission 
rates were lower than in the public hospital, and all admittances were accounted for. 





7. FURTHER PERSPECTIVES 
The ARRA-RACS is the first prospective, observational study of 
admitted chest pain patients held in the province of Salta. Consistent with available 
information, we showed that traditional risk factors and biomarkers measured at 
admission are associated with 2-5 year mortality in our cohort of patients. 
Socioeconomic disparities in the study population also reflect 
disparities in the care of patients. This is associated with a worse prognosis in those 
patients without a healthcare insurance, accounting for approximately 60% of the 
general population in Argentina.  
We also found that the levels of omega-3 index and vitamin D were 
very low in this almost uniquely beef eating population, suggesting that other 
threshold values related to cardiovascular risk should be considered in these 
individuals as compared to a fish eating population. Likewise, pharmacological 
intervention studies would be interesting to perform, both in primary and secondary 
prevention, in a cohort of patients with low levels of omega-3 index and vitamin D. 
Based on this study, several implications and recommendations for 
public education, cardiovascular research, medical care, and public policy have 
emerged, as follows:   
 Public education: the need to develop and implement an educational program, 
addressing not only reduction of specific cardiovascular disease risk factors, 
but also the societal conditions that lead to the adoption and maintenance of 
high-risk behaviors. 
 Research: the quest for a better understanding of the links between economic 
policy, healthcare coverage, unemployment, and other economics phenomena 
and the prevention, incidence, treatment and follow-up of cardiovascular 
disease. Furthermore, particular attention should focus on the impact of 
socioeconomic status throughout a lifespan, including its influence during the 
prenatal and early-childhood stage.  
 Medical care: the need to aggressively address preventive services, education 
and follow-up programs targeted toward the lower socioeconomic groups.  
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 Public policy: the need to establish a healthcare program for all inhabitants 
should be addressed by the government and raised as a political issue. 





8.  CONCLUSIONS 
1. Paper 1 
The rate of total- and cardiac death was elevated in chest pain patients 
with suspected ACS belonging to the lowest socioeconomic class, and was not 
only related to the lack of a social security program.    
 
2. Paper 2 
BNP and hsCRP may act as clinically useful prognostic biomarkers 
when obtained at hospital admission in an unselected chest pain population 
with potential ACS, and may improve risk stratification in troponin positive 
patients. However, these biomarkers failed to identify patients at risk in the 
troponin negative population. 
 
3. Paper 3 
Vitamin D was shown to be a useful biomarker for prediction of 
mortality when obtained at admission in chest pain patients with suspected 
ACS. 
 
4. Paper 4   
In a population with a very low intake of fish and fish oils, the omega-
3 index did not predict future fatal events in patients with acute chest pain 
and suspected ACS. 
 
5. General Conclusion  
Thus, the traditional risk markers BNP and hsCRP behaved as 
prognostic indicators in this prospectively studied cohort of chest pain 
patients with suspected ACS. Vitamin D levels and socioeconomic class were 
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